{
    "clinical_study": {
        "@rank": "105741", 
        "arm_group": {
            "arm_group_label": "GDC-0973 Single Arm", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, non-randomized study will assess the absorption, metabolism, an d excretion\n      of radioactive-labeled [14C]-GDC-0973 in healthy male volunteers. Vo lunteers will receive a\n      single dose of [14C]-GDC-0973."
        }, 
        "brief_title": "A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body mass index (BMI) between 18.5 and 29.9 kg/m2, inclusive\n\n          -  No clinically significant findings from medical history, 12-lead ECG, and vital signs\n             and laboratory evaluations\n\n          -  Negative test for selected drugs of abuse\n\n          -  No infection with hepatitis B, hepatitis C, human immunodeficiency virus (HIV)\n\n          -  Sterile or agree to use an adequate contraception method\n\n          -  Historically able to produce a minimum of 1 bowel movement per day\n\n        Exclusion Criteria:\n\n          -  Significant history or clinical manifestation of any significant metabolic, allergic,\n             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,\n             gastrointestinal, neurological, or psychiatric disorder\n\n          -  History of significant hypersensitivity, intolerance, or allergy to any drug\n             compound, food, or other substance unless approved by the Investigator\n\n          -  History of stomach or intestinal surgery or resection (including a cholecystectomy)\n             that would potentially alter absorption and/or excretion of orally administered drugs\n             except that appendectomy and/or hernia repair will be allowed\n\n          -  History of Gilbert's Syndrome\n\n          -  History of diabetes mellitus and/or elevated fasting glucose at baseline\n\n          -  History or presence of an abnormal ECG\n\n          -  History of alcoholism or drug addiction within 1 year prior Check-in\n\n          -  Participation in more than one other radiolabeled investigational study drug trial\n             within 12 months prior to Check-in\n\n          -  Exposure to significant radiation within 12 months prior to Check-in study drug\n             occurred within 5 half-lives or 30 days, whichever is longer, prior to Check-in\n\n          -  Use of any tobacco-containing or nicotine-containing products within 6 months prior\n             to Check-in\n\n          -  Participation in any other investigational study drug or biologic agent trial in\n             which receipt of an investigational study drug occurred within 5 half-lives or 30\n             days, whichever is longer, prior to Check-in\n\n          -  Use of any prescription medications/products within 14 days prior to Check-in"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711762", 
            "org_study_id": "GP28369"
        }, 
        "intervention": {
            "arm_group_label": "GDC-0973 Single Arm", 
            "description": "Single oral dose of [14C]-GDC-0973", 
            "intervention_name": "GDC-0973", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53704"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0973 Following Single Oral Dose Administration in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Route of elimination of [14C]-GDC-0973", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 weeks"
            }, 
            {
                "measure": "Pharmacokinetics: maximum observed concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 weeks"
            }, 
            {
                "measure": "Pharmacokinetics: time to maximum concentration (tmax)", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 weeks"
            }, 
            {
                "measure": "Pharmacokinetics: area under the concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 weeks"
            }, 
            {
                "measure": "Pharmacokinetics: apparent terminal elimination phase rate constant", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 weeks"
            }, 
            {
                "measure": "Pharmacokinetics: apparent terminal elimination phase half-life", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 weeks"
            }, 
            {
                "measure": "Pharmacokinetics: apparent total clearance", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 weeks"
            }, 
            {
                "measure": "Pharmacokinetics: apparent volume of distribution", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 weeks"
            }, 
            {
                "measure": "Pharmacokinetics: amount total radioactivity in whole blood/urine/feces", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711762"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: quantification of GDC-0973-related metabolites in plasma, urine and fecal homogenates", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 weeks"
            }, 
            {
                "measure": "Pharmacokinetics: plasma concentration of GDC-0973", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 weeks"
            }, 
            {
                "measure": "Safety: incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 weeks"
            }
        ], 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}